IMMUNO-ONCOLOGY, INCLUDING CELL-BASED THERAPIES
Lieping Chen, MD, PhD
Codirector, Cancer Immunology Program, Yale Cancer Center
    Lieping Chen, MD, PhD, has been integral to the discovery of the PD-1/PD-L1 pathway and its immune-suppressive functions.
    • Dr. Chen has established himself as an expert in the field of lymphocyte costimulation and coinhibition and the use of this knowledge to battle cancer.
    • He and his laboratory are credited with the codiscovery of the PD-1/PD-L1 pathway. More important, his laboratory performed foundational work that led to the invention of new immuno-oncology therapy. These works include understanding of the PD-L1 expression in tumor microenvironment as an escape mechanism from immune attack and the proof-of-principle experiments of anti–PD-1/PD-L1 antibody therapy.
    • He also pioneered the first in-human trial of an antibody blockade of the PD-1/PD-L1 pathway, which involved nivolumab (Opdivo), and he invented the PD-L1 staining to predict the outcome of treatment. Anti–PD-1/PD-L1 therapy has since been employed against a broad spectrum of at least 25 types of cancer.
    • Many other important pathways have been identified in Dr. Chen’s laboratory, including 4-1BB, ICOS/B7-H2, B7-H3, B7-H4, B7-H5/CD28H, PD-1H, LIGHT/HVEM, TROY, B7-H2/CD28/CTLA-4 (human), and SALM5/HVEM.
Program Information:
Nominate
Sponsor
News
Previous Inductees:
2013 | 2014
2015 | 2016
2017 | 2018
Connect: